PredxBio Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Accelerator/Inc
- Latest Deal Amount
-
$300K
- Investors
-
14
PredxBio General Information
Description
Operator of a software platform intended to transform complex tissue and biological data into decision-ready insights for biopharma and diagnostics organizations. The company's platform applies advanced spatial analytics and explainable AI (artificial intelligence) to interpret tissue architecture, cellular interactions, and biological context, enabling biopharma and diagnostics teams to support translational research, biomarker strategy, and clinical development with actionable evidence for program decisions.
Contact Information
Website
www.predxbio.comCorporate Office
- 100 South Jackson Avenue
- Pittsburgh, PA 15202
- United States
Corporate Office
- 100 South Jackson Avenue
- Pittsburgh, PA 15202
- United States
PredxBio Timeline
PredxBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Accelerator/Incubator | $300K | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series A2) | 02-Jul-2025 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series A1) | 01-Apr-2024 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series A1) | 22-May-2023 | Completed | Product Development | |||
| 6. Seed Round | 02-Feb-2021 | Completed | Product Development | |||
| 5. Accelerator/Incubator | Completed | Product Development | ||||
| 4. Accelerator/Incubator | 01-Jan-2020 | Completed | Product Development | |||
| 3. Seed Round | 06-Aug-2019 | Completed | Product Development | |||
| 2. Grant | 21-Mar-2019 | $225K | $400K | Completed | Product Development | |
| 1. Seed Round | 06-Sep-2018 | $400K | $400K | Completed | Startup |
PredxBio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series B-1 | ||||||||
| Series B-2 | ||||||||
| Series A-1 | ||||||||
| Seed 3 | ||||||||
| Seed 2 | 207,757 | $0.001000 | $0.08 | $1.35 | $1.35 | 1x | $1.35 | 5.21% |
| Seed 1 | 260,774 | $0.001000 | $0.07 | $1.18 | $1.18 | 1x | $1.18 | 6.54% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
PredxBio Comparisons
Industry
Financing
Details
PredxBio Competitors (9)
One of PredxBio’s 9 competitors is Nucleai, a Venture Capital-Backed company based in Chicago, IL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nucleai | Venture Capital-Backed | Chicago, IL | ||||
| BioAI | Venture Capital-Backed | Manchester, NH | ||||
| Visiopharm | Private Equity-Backed | Hoersholm, Denmark | ||||
| Elucidate Biotechnologies | Corporation | Boston, MA | ||||
| Enable Medicine | Formerly VC-backed | San Francisco, CA |
PredxBio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
PredxBio Patents
PredxBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3133689-A1 | An explainable ai (xai) platform for computational pathology | Pending | 15-Mar-2019 | ||
| EP-3938951-A1 | An explainable ai (xai) platform for computational pathology | Pending | 15-Mar-2019 | ||
| JP-2022527240-A | Explainable ai (xai) platform for computational pathology | Pending | 15-Mar-2019 | ||
| US-11367184-B2 | Explainable ai (xai) platform for computational pathology | Active | 15-Mar-2019 | ||
| US-11842488-B2 | Explainable ai (xai) platform for computational pathology | Active | 15-Mar-2019 | G06T7/0012 |
PredxBio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
PredxBio Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Central Texas Angel Network | Angel Group | Minority | ||
| Concordance Technology | Venture Capital | Minority | ||
| Elmstead Partners | Corporation | Minority | ||
| Global Venture Bridge | Family Office | Minority | ||
| NW Angel | Venture Capital | Minority |
PredxBio FAQs
-
When was PredxBio founded?
PredxBio was founded in 2017.
-
Where is PredxBio headquartered?
PredxBio is headquartered in Pittsburgh, PA.
-
What is the size of PredxBio?
PredxBio has 7 total employees.
-
What industry is PredxBio in?
PredxBio’s primary industry is Other Healthcare Technology Systems.
-
Is PredxBio a private or public company?
PredxBio is a Private company.
-
What is PredxBio’s current revenue?
The current revenue for PredxBio is .
-
How much funding has PredxBio raised over time?
PredxBio has raised $9.2M.
-
Who are PredxBio’s investors?
Central Texas Angel Network, Concordance Technology, Elmstead Partners, Global Venture Bridge, and NW Angel are 5 of 14 investors who have invested in PredxBio.
-
Who are PredxBio’s competitors?
Nucleai, BioAI, Visiopharm, Elucidate Biotechnologies, and Enable Medicine are some of the 9 competitors of PredxBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
